Sepsis
Conditions
Interventions
A prospective study was carried out divided into two quarters (Group A and Group B). In group A, the control group and in group B, the group undergoing therapy guided by Procalcitonin. A comparative s
Other
N04.590.874.500
Sponsors
Universidade Federal de Sergipe
Hospital Universitário de Lagarto
Eligibility
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients with suspected sepsis; hospitalized in critical areas (yellow, red clinic and ICU); Older than 18 years; Not pregnant.
Exclusion criteria
Exclusion criteria: Pregnancy discovered during collection; infections requiring prolonged antibiotic therapy, such as endocarditis, liver or brain abscess, deep abscess, mediastinitis and osteomyelitis; severe infection caused by viruses, parasites, fungi or mycobacteria; negative cultures (blood, urine, tracheal aspirate, or bronchoalveolar lavage) in patients with suspected sepsis, severe sepsis or septic shock.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to reduce the days of treatment with antibiotics and also to reduce the days of hospitalization between two groups, procalcitonin and control. Using the PRORATA method of the study by Bóuadma (2010), a large and complex study carried out in intensive care units. According to the procalcitonin serum level protocol, if the concentration is less than 0.25 µg / L, we suggest if you stop antibiotics; if less than or equal to 0.25 and less than 0.5 µg / L or greater than or equal to 80% of peak decrease, it is suggested to stop antibiotics encouraged; if it is greater than or equal to 0.5 µg / L or less than 80% of the peak decrease, continued stimulated antibiotics are suggested; and, if it is greater than or equal to 0.5 µg / L, increasing the peak, it is suggested to change antibiotics. Through this method, it was found that procalcitonin reduced exposure to antibiotics by 23%, but that it did not have a significant effect on mortality outcomes at the time. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to assess the economic impact during the first and second quarter of the study, as well as the study Deliberato et al. (2013), the total amount spent on antibiotic therapy in both groups will be used, plus the amounts spent on procalcitonin dosages (in the procalcitonin group only) and divided by the number of patients included in each group. | — |
Countries
Brazil
Contacts
Public ContactPhydel Carvalho
Universidade Federal de Sergipe
Outcome results
None listed